Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease ...
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) diseases, today announced that its President and Chief
Executive Officer, Christopher U. Missling, PhD, will join the
panel, “Industry and Advocacy Collaborations ─ Making it a
Win-Win”, at the National Institutes of Health (NIH) virtual Rare
Disease Day® event on Monday, March 1st at 11:35 a.m. EST. There
will be a live Q&A following the panel discussion.
Rare Disease Day® takes place every year on the
last day of February, with several international events extending
into March. The event at the NIH is sponsored by the National
Center for Advancing Translational Sciences and the NIH Clinical
Center. Rare Disease Day® at NIH aims to raise awareness about rare
diseases, challenges and research underway. The event brings
together all stakeholders involved in advancing research and
therapeutic development for rare diseases and includes patients,
rare disease families, patient advocacy professionals, healthcare
providers, academic researchers, members of the biopharmaceutical
industry, and government representatives.
Rare Disease Day® at NIH will be held virtually
on Monday, March 1st, 2021, from 10:30 a.m. to 5:30 p.m. EST. This
year’s event will feature interactive panel discussions, rare
stories through TED-style talks and more. The event is free and
open to the public, including patients, patient advocates, health
care providers, researchers, trainees, students, industry
representatives and government employees.
Click here to register or to learn more about
About Rare Disease Day® at
Rare Disease Day at NIH aims to raise awareness about rare
diseases, the people they affect, and NIH research collaborations
underway to address scientific challenges and to advance new
treatments.The goals of Rare Disease Day at NIH are to:
- Demonstrate the NIH commitment to helping people with rare
diseases through research.
- Highlight NIH-supported rare diseases research and the
development of diagnostics and treatments.
- Initiate a mutually beneficial dialogue among public and
private researchers, patients, patient advocates and
- Exchange the latest rare diseases information with stakeholders
to advance research and therapeutic efforts.
- Put a face on rare diseases by sharing stories of patients,
their families and their communities.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, pain and various types of
cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine),
recently completed successfully a Phase 2a clinical trial for
Alzheimer’s disease and a Phase 2 proof-of-concept study in
Parkinson’s disease dementia and a Phase 2 study in adult patients
with Rett syndrome. ANAVEX®2-73 is an orally available drug
candidate that restores cellular homeostasis by targeting sigma-1
and muscarinic receptors. Preclinical studies demonstrated its
potential to halt and/or reverse the course of Alzheimer’s disease.
ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research previously awarded Anavex a research grant, which fully
funded a preclinical study to develop ANAVEX®2-73 for the treatment
of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and
muscarinic receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook and LinkedIn.
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
BarwickiInvestor Relations Tel: 516-662-9461 Email: